KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Current Deferred Revenue (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Current Deferred Revenue for 16 consecutive years, with $2.7 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Current Deferred Revenue rose 4.55% year-over-year to $2.7 billion, compared with a TTM value of $2.7 billion through Sep 2024, up 4.55%, and an annual FY2023 reading of $2.7 billion, up 3.38% over the prior year.
  • Current Deferred Revenue was $2.7 billion for Q3 2024 at Thermo Fisher Scientific, up from $2.6 billion in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.7 billion in Q3 2022 and bottomed at $938.0 million in Q1 2020.
  • Average Current Deferred Revenue over 5 years is $2.2 billion, with a median of $2.6 billion recorded in 2024.
  • The sharpest move saw Current Deferred Revenue decreased 8.19% in 2020, then skyrocketed 108.89% in 2021.
  • Year by year, Current Deferred Revenue stood at $1.3 billion in 2020, then surged by 108.89% to $2.7 billion in 2021, then dropped by 2.03% to $2.6 billion in 2022, then rose by 3.38% to $2.7 billion in 2023, then dropped by 0.97% to $2.7 billion in 2024.
  • Business Quant data shows Current Deferred Revenue for TMO at $2.7 billion in Q3 2024, $2.6 billion in Q2 2024, and $2.6 billion in Q1 2024.